Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 1,402 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: SoC Clear all
Terminated No phase listed Observational

Sinus Augmentation With Dental Implant

NCT00991393
View directory record Official record
Conditions
Maxillary Sinus Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
5
States / cities
Fullerton, California • Denver, North Carolina • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2012 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Community Collaboration to Combat COVID-19 (C-FORWARD)

NCT04673292
View directory record Official record
Conditions
Coronavirus Infection
Interventions
Fixed site standard of care testing, Community-based, mobile van testing, Self-collected, home-based testing
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years and older
Enrollment
831 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2024 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 1 Interventional

Momelotinib During and After HCT in Myelofibrosis

NCT07104799
View directory record Official record
Conditions
Myelofibrosis, Hematopoietic Cell Transplantation (HCT)
Interventions
Momelotinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Terminated Not applicable Interventional Results available

Irrisept Versus Standard of Care in the Prevention of Surgical Site Infections

NCT02255487
View directory record Official record
Conditions
Surgical Site Infection
Interventions
IrriSept System, No Intervention - Standard of Care (SoC) only
Device · Other
Lead sponsor
Irrimax Corporation
Industry
Eligibility
18 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

VisionRT-based Deep Inspiration Breath-hold (DIBH) Respiratory Motion Management Strategy, A Pilot Study for Thoracic and Abdominal Tumors

NCT04686500
View directory record Official record
Conditions
Thoracic Cancer, Abdominal Cancer
Interventions
Tidal volume measured by spirometer and DIBH surface from CT image
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 28, 2026, 9:39 AM EDT
Active, not recruiting Phase 2 Interventional

Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

NCT05419011
View directory record Official record
Conditions
Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
Interventions
Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Results available

Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients

NCT03927144
View directory record Official record
Conditions
Episodic Migraine
Interventions
AMG334, Oral Prophylactic
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Stanford, California • New Haven, Connecticut • Stamford, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 1 Interventional

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

NCT06959706
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
TGW101
Drug
Lead sponsor
Tagworks Pharmaceuticals BV
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Philadelphia, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 2 Interventional

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07761910
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
Interventions
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
Diagnostic Test · Device · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of Primary Sampling Scatter Correction for Chest Tomosynthesis

NCT04076696
View directory record Official record
Conditions
Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple
Interventions
Scatter corrected s-DCT
Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions
Placebo, SHP655, Standard of Care
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 28, 2026, 9:39 AM EDT
Active, not recruiting Phase 2 Interventional

MMRC Horizon One: RRMM (MMRC-099)

NCT06171685
View directory record Official record
Conditions
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Teclistamab Monotherapy, Teclistamab
Drug
Lead sponsor
Multiple Myeloma Research Consortium
Network
Eligibility
18 Years to 99 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Terminated Not applicable Interventional

Studying Survivorship Care Plans in Head and Neck Cancer

NCT03106090
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
educational materials
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 28, 2026, 9:39 AM EDT
Terminated Phase 1 Interventional Results available

Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia

NCT03862040
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Cefiderocol, Standard of Care Antibiotic
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
7
States / cities
Aurora, Colorado • Hartford, Connecticut • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 4 Interventional

Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Matched Standard of Care Controls in the Management of Nonhealing Pressure Ulcers

NCT06999590
View directory record Official record
Conditions
Pressure Ulcer, Ulcer, Ulcer, Pressure, Pressure Injury
Interventions
ACApatch™, caregraFT™, Standard of Care
Other
Lead sponsor
Tiger Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 1 Interventional

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

NCT05270213
View directory record Official record
Conditions
Advanced Cancer
Interventions
RBS2418, Pembrolizumab, Other approved anti-cancer therapy
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Phase 1 Interventional

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

NCT03162250
View directory record Official record
Conditions
Bacteremia
Interventions
DSTA4637S, Placebo, SOC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting

NCT02037594
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Sexual Health Counseling, Enhanced Adherence Intervention, PrEP Information (Active Control), Standard of Care Adherence Support (Active Control)
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years and older · Male only
Enrollment
438 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 28, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections

NCT06369220
View directory record Official record
Conditions
Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
Interventions
cobas® liat CT/NG/MG nucleic acid test, Standard of Care (SOC): Clinician's Standard Practice
Diagnostic Test · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
San Francisco, California • Hamilton Square, New Jersey • Perth Amboy, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Not applicable Interventional

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

NCT07188532
View directory record Official record
Conditions
Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
Interventions
Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection, Dose-escalated Radiation Therapy, Electronic Health Record Review, External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 2 Interventional

Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

NCT06638944
View directory record Official record
Conditions
Dysphagia, Stroke, Parkinson Disease
Interventions
In-person sEMG-biofeedback, Remote sEMG-biofeedback, Standard-of-care treatment
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
50 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Champaign, Illinois • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Not yet recruiting Not applicable Interventional

Clinical Evaluation of an Alarm Activated Detection System to Enable Early Intervention of Emerging Respiratory Decline With the Linshom Medical Continuous Predictive Respiratory Sensor (CPRS)

NCT07793981
View directory record Official record
Conditions
Post Surgical Respiratory Failure, Respiratory Complication, Opioid Induced Respiratory Depression, Respiratory Arrest
Interventions
Linshom Continuous Predictive Respiratory Monitoring
Device
Lead sponsor
Linshom Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Recruiting Phase 2 Interventional

Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma

NCT07497607
View directory record Official record
Conditions
Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Sara Medek
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 28, 2026, 9:39 AM EDT
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 28, 2026, 9:39 AM EDT